Summit Estate’s very own clinical consultant Dr. Kenneth Blum, M.Sc, DHL, was the lead author of an article recently published in Current Pharmaceutical Design medical journal. Dr. Blum and his collaborators believe they may be onto the “hatching of the addiction egg” with their research. Current Pharmaceutical Design publishes in-depth reviews that involve modern research on rational drug design. Each issue of Current Pharmaceutical Design is focused on a single therapeutic area, covering subjects important to modern drug design such as:
- Medicinal Chemistry
- Disease Mechanism
- Drug Targets
Solving America’s Addiction Epidemic
The new Dr. Blum-led article is titled, “Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity.” Ultimately, the article aims to further the understanding of common mechanisms of all types of addiction in order to foster better diagnoses, treatment and prevention of relapse. The authors raise a number of questions before delving further into the research, such as:
- Why are medical professionals failing at reducing the incidence of “bad behaviors”?
- Are we aiming at the wrong targets for the treatment of behavioral disorders?
Quick Background On ‘Reward Deficiency Syndrome’
In 1996, Dr. Blum and his research team coined the term “Reward Deficiency Syndrome” (RDS) to explain the neurochemical and genetic mechanisms involved in addictive behaviors, including substance and process addictions. A few years prior, Dr. Blum was involved in identifying the connection between the dopamine D2 receptor and severe alcoholism. In his new article, Dr. Blum points to a past study which observed that habitual cocaine use was connected with a reduction in dopamine D2 and D3 receptors. He and his team also maintain that medication-assisted treatment with an emphasis on anti-dopamine (or dopamine antagonist) medications, such as those involving clozapine, fails in the long run when it comes to RDS behaviors.
Homeostasis Over Antagonist Therapy
When it comes to treating addiction, Dr. Blum and his fellow researchers propose using dopamine antagonist therapy in the short term, and dopamine agonist therapy in long term recovery. Put simply, it’s better to try to keep the recovering addict’s dopamine levels fairly stable over the long term than to stunt the neurotransmitter altogether.
“The neuro-mechanisms involving ‘dopamine homeostasis’ are key to understanding recovery from drug and non-drug addictive behaviors,” Dr. Blum writes.
Amino Acid Therapy Could Be Key
In the article, Dr. Blum and his team identify a particular allele for which neuronutrient-amino acid therapy would be beneficial if the host is suffering from addiction. Amino acids help balance brain chemicals and other parts of human physiology. The article also points out a number of gene polymorphisms that lead to a heightened risk of all RDS behaviors.
The Importance Of Dr. Blum’s New Addiction Study
Dr. Blum and his fellow researchers conclude that paying attention to addicts’ dopamine levels is essential to better understanding the science of addiction. They encourage medical professionals to look for a certain allele in their patients that indicates a high risk for addiction, as amino acid therapy appears to be an effective treatment for people who carry this particular gene variant. The authors finish with a call for more genetic and neuroimaging studies as they pertain to drug addiction. If that were to happen, Dr. Blum and his colleagues believe that neuroscientists will actually hatch “the addiction egg.” To learn more about Dr. Kenneth Blum, see our Staff Page.